Compare LEU & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEU | ACAD |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | 1998 | 2000 |
| Metric | LEU | ACAD |
|---|---|---|
| Price | $204.23 | $22.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 22 |
| Target Price | ★ $248.82 | $30.55 |
| AVG Volume (30 Days) | 707.1K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 3.90 | 2.30 |
| Revenue | $193,000,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $3.76 | $18.80 |
| Revenue Next Year | $6.04 | $11.70 |
| P/E Ratio | $51.94 | ★ $9.24 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $60.52 | $14.08 |
| 52 Week High | $464.00 | $28.35 |
| Indicator | LEU | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 51.74 |
| Support Level | $187.56 | $20.22 |
| Resistance Level | $219.85 | $23.06 |
| Average True Range (ATR) | 12.60 | 0.73 |
| MACD | 3.89 | 0.07 |
| Stochastic Oscillator | 86.38 | 69.59 |
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.